Tarveda Therapeutics to Present at the 2018 Biotech Showcase

Dec. 20, 2017 13:00 UTC

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tarveda Therapeutics, a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 10th Annual Biotech Showcase, occurring January 8-10, 2018 at the Hilton Union Square in San Francisco.

The presentation will take place at 10:00am Pacific Time on Wednesday, January 10 in Franciscan - D.

In the presentation, Mr. Fromkin will address the Company’s Pentarin miniature drug conjugate platform including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive cancers including neuroendocrine and small cell lung cancers, and PEN-866, an HSP90 targeting conjugate, which is being developed for the treatment of patients with a wide range of solid tumors including pancreatic cancer, small cell lung cancer and sarcoma.

About Pentarins™

Tarveda is developing Pentarins™, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell-killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell-killing payload inside the cancer cells for efficacy.

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities for the treatment of a wide range of solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, prostate, small cell lung and other cancers that express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2 conjugated to the potent cytotoxic DM1 through a tuned cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38, the highly potent active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarveda.com



MacDougall Biomedical Communications
George E. MacDougall, 781-235-3060


Source: Tarveda Therapeutics, Inc.

Back to news